Member Info for The_Paladin

“I find most updates are given when there’s something to update.”

I find it odd that it will have taken until the last millisecond of H2 - the fuzzy deadline that Mr. Marsden gave himself (with certain provisos) at the end of last September. To add further context, it is now 28 months since the failure of the Sprinter trial, and there no measurable progress has been made since then!

Investors are in need of an update, stating clearly the progress that the company has made on their stated objectives since last September.

Mr.Marsden’s fuzzy obfuscation has kept him in his role for 28 months. The cash reserves are running low, and the share price is at a corresponding low level. There is no confirmation of any progress since February 2022. ( Poster presentations and published papers do not add to the company’s MCap! )

We need to know about the progress made on patient identification for the proposed company trials? Additionally, details of the arrangements secured with so called “partners” to enable further progress to be made?

We have had enough of hearing about the latter initiatives in a hypothetical sense. It is high time for us to be informed about the precise measures planned for these to come about, with timelines and deadlines included.

The selling to date this week shows that my worst suspicions are being realised. LTIs like myself can either sell up at a loss, or wait and see how a certain individual intends to add incrementally to his personal fortune - at the expense of IQ-AI investors.

Is there long term potential here? Had a different course of action been enabled at the start of the year, could we have been heading north by now? The current state of play does not correlate to the news emerging from IB? Is this being deliberately suppressed so that a certain individual can maximise his return? Otherwise, has this company less to offer investors than we have been led to believe?

Thank you for sharing TraderNick,

The first part is a précis of what we were told last September. Reporting full year results in Q2, 2024 is a statutory requirement.

It will be disappointing if the next update contains the substance of the recent poster presentations, and the COPD trial publication as she operational highlights? This month’s reporting should aLeo include the usual Grant Of Options RNS.

It will be good if Synairgen are able to finally break free from their period of 28 months of no real achievement, and offer something substantial, that will finally take the company forward!

GLALTIs.

Finally, it seems that there is no problem on that front!

Are some investors still maintaining a countdown to the end of H1, 2024 with possible trial news on our horizon? Or has our focus now shifted to a possible joint venture / licensing arrangement with a major biopharmaceutical company?

Some of us have, thankfully, sounded positive notes during today’s dialogue. This investment may yet turn a corner to benefit us all?

But first, Synairgen really need to inform us as to what has been going on during the last eight months or so? It has been a long wait with no updates whatsoever!

GLALTIs.

Fnv.

Your arguments make sense. However, we are unfortunate in having a precedent of unnecessary hiring prior to the results of the Sprinter trial. This was carried out in anticipation of a positive trial outcome.

Similarly, the hiring at the end of last year may well have been carried out with subsequent successful negotiations to move SNG001 towards further trialling in mind?

The principle is sound. Whether the CEO and his executives have the ability to bring it about is another question? It has been over 27 months since the Sprinter outcome. Since then, they have delivered nothing!

As ever, I hope that I am incorrect in my reading of the current situation.

……. shown by an untrustworthy individual and his acolytes? The relatively large trade at a low price this morning may be the start of a sell off strategy to take the share price lower? We all know by now what this will lead to!

Whatever is going on is being conducted at the last millisecond. The usual well established procedures regarding perfunctory announcements have not been adhered to.

I have had doubts about the abilities of the CEO and his acolytes for a long time. In my worst thoughts, I see them as bluffers, who have remained in situ for their own benefit. My contributions to this forum have been far from positive for that reason.

I still hope that there will be a satisfactory resolution to our situation to benefit all LTIs, but am having serious doubts this morning.

GLALTIs.

It will need to contain far more than the statutory announcement in 2022.

There needs to be a significant update either concerning P2 trialling, or else a binding agreement of some description, with a large biopharmaceutical entity.

Otherwise, nothing of value will have been achieved since last September. Best to remain positive, until we hear otherwise.

GLALTIs.

We have probably reached the point where it is too late to commence P2 trials during Q2, 2024. The poster presentation at ATS 2024 was sadly just that. I had hoped that it would be quickly followed by an RNS statement concerning the proposed trials.

Like some other investors, I have all but given up on the CEO and his executives. They evidently lack the ability and wherewithal to take SNG001 forward to further trialling. Nothing of any material benefit to investors has happened as the result of their assumed activity over the last 27 months.

Our best hope appears to lie with TFG Holdings, and their next steps. Should they “persuade” the company to place their valuable IP in the hands of a major biopharmaceutical entity to everyone’s benefit, we may have an opportunity of recouping some of our losses? Perhaps I am being naive in thinking that anything of this nature could happen?

As always, I shall, as ever, be happy to learn that my pessimism regarding the company’s leadership was incorrect, and unfounded. A long running saga, with nothing whatsoever achieved, and very little dialogue with investors has brought this about.

GLALTIs.

All Synairgen investors will be relieved to learn when the results of a significant study will contribute to the patient protocols for the company’s forthcoming P2 trials. I look forward to that announcement, particularly if it reinvigorates the company, and its share price in particular.

The statement “ Synargen have been doing more than some would summarise ” is a curious comment, especially coming from someone with more detailed knowledge about the company than most investors.

We have known about Synairgen’s role in the Universal study since its inception.

“Synairgen is providing viral testing equipment and nursing staff at the Southampton clinical trial site.”

Pedro Rodriguez, whose name is included on the publication, is a Clinical Research Nurse Manager and Junior Project Manager at Synairgen. It seems more than likely that he has been seconded by Synairgen to lend his expertise to the study, as stated above.

My optimism for a favourable outcome to my investment remains. It is such a shame that some investors, who still maintain a high degree of confidence in the company’s leadership, choose to constantly contradict others, who are more reserved in their opinion.

The only important factor is that Synairgen progresses towards a successful endpoint to the benefit of its investors.

GLALTIs.

There is nothing bewildering about any of my statements, nor those of other valued contributors. Unfortunately, the expert on diversionary tactics invariably attempts to make light of our opinions because they don’t tally with his worldview.

This is a discussion board where individuals are free to offer their opinions. Many choose to quote supportive evidence through unconnected scientific papers to validate their thoughts. Not one of these has added a cent to the Synairgen share price, as they are not linked directly to our investment case.

I hope that our self-proclaimed expert, who attempts to denigrate the views of others through attempted witticisms is correct on this occasion.

Investors are in serious need of a meaningful update from Synairgen. The CEO and his leadership team have produced nothing of value in 27 months. This is evidenced by the continuous decline in the share price to the current level!

GLALTIs.

At 07:00 I was anticipating an RNS linking today’s ATS 2024 poster presentation to the trial protocols for the expected company P2 trials - scheduled to start before the end of June 2024.

Since May 23, 2023, Synairgen have issued 8 RNS statements. The last of these was on November 15, 2023. They include announcing an annual report and AGM date on May 23, 2023. This year’s equivalent statement is surely due this week or next?

Perhaps when it is released, it will enlighten investors about the expected P2 trials? There really has been nothing of substance in the last year. The eight RNSs are common or garden, and include two statements of Grant of Options statements and two announcing appointments to the Senior Leadership Team.

It really is concerning that we are approaching the end of H1 2024, and there has been little announced in a whole year apart from two recent poster presentations in which nothing substantially new his being offered? Neither of these has merited an RNS.

GLALTIs.

Professional.

I have no idea how this investment will proceed? However, given the right news ( hopefully during Q2?), I am anticipating an initial rise well in excess of £0.20. It all hinges on what Synairgen have achieved during the last 7+ months?

I agree with JD in that I couldn’t discern anything new in the ATS abstract. As I am not qualified to offer an opinion, I requested other more knowledgeable investors for their views earlier today. As I read it, the general consensus is positive, and I look forward to receiving further clarification from Synairgen when they are ready to enlighten us?

As stated, we will be on our way, given the right news, but for the moment I am remaining guardedly optimistic.

GLALTIs.

Thank you for posting the link Owl11.

"Analysis of Baseline Factors Associated With Poor Clinical Outcome in a Phase 3 Trial in Patients Hospitalized Due to COVID-19."

The lead author of the presentation is Dr. V Tear, who is a senior scientist at Synairgen and an experienced participant at Synairgen poster sessions. I note that she attended the UKHSA/SNG poster presentation at the Microbiology. Society Annual Conference in Edinburgh, and was a co-presenter, with Prof Tom Wilkinson, of the first Host Directed podcast. She is likely to be the lead presenter, being the contact person regarding the abstract. Her obvious competence adds to my confidence that the message will get through to interested (hopefully significantly so) attendees at the ATS 2024 conference.

I have read Dr Tear's abstract, but am not qualified to comment on its significance. Is this presentation leading to what we are all expecting, namely Synairgen's patient protocols for the expected forthcoming P2 trials? I would appreciate a brief comment from our more knowledgable contributors, who frequently offer scientific content to this forum, should you have the time, that is. Should it be the first step towards the protocols for the aforementioned trials, it will come as a welcome relief!

Thank you for your response wpa5. As always, your opinion is appreciated. I am as yet uncertain whether I would remain invested beyond a break even point, should that be achieved? My reasoning is simple. I did just that between December 2021 - February 2022, when I could, and should have sold my Synairgen stock for a profit. I retain a high level of confidence in SNG001, but unfortunately not in Synairgen's CEO and Board. Wheres I own my current paper losses, I doubt whether I would now trust the company beyond a break-even/return to profit level. It is still early days though. Nothing new has been shared with investors for well over two years. A significant piece of information from the company could well change my opinion.

GLALTIs.

Fnv.

Should the route towards approval and commercialisation result in a profit ( or even a break-even point) from the current position, I will be happy. I believe that I am right in thinking that all investors, like myself, who were over invested prior to the Sprinter trial outcome, and sustained losses as a result, will have a similar point of view.

Agreed, more deliberate manipulation to satisfy the ongoing greed of a small number of individuals.

They have lost sight of the importance of the company’s IP. This could eventually be of enormous benefit to a large number of seriously ill people.

Instead of promoting and developing the company, these sharks are continuing to use it purely to increase their wealth. What sad pathetic individuals they all are!

It is not a case of loyalty. That is something that is earned, and the CEO and Board have done little or nothing to deserve any loyalty from shareholders,

It is a case of maintaining a belief in the company’s core product, and its future as an important broad- spectrum antiviral treatment. A worldwide need for it exists. Should the company’s current strategy/negotiations - whatever is actually going on during the current level by term silence? - result in a good outcome for investors, I will be well satisfied.

Personally, I don’t give two hoots about the CEO and his acolytes, as they have treated shareholders shabbily for far too long. Should their actions, however inappropriate, result in a good profit, that is all that matters to me.

GLALTIs.

I noted that the BRH share price was down by > 40% this morning following an RNS about the revaluation of its assets. It would appear that TB commands the same level of respect from BRH investors as is the case here. Leopards and spots spring to mind.

I remain optimistic of an eventual decent return here, although I don't see the point of the IB LinkedIn messages, which attract practically no attention. How long will it take before we receive detailed notification of recent sales, and growth figures?

GLALTIs.

Our last significant update in September 2023 included the following:

"Conducting non-interventional preparatory work to expand hospitalised patient populations for potential treatment with SNG001, which are likely to include: ventilated patients with confirmed viral pneumonia; and patients who are unable to clear virus and become persistent viral "shedders", a majority of whom are immunocompromised. Subject to this preparatory work and regulatory approval timelines, trials are anticipated to start in H1 2024."

It is not unreasonable to deduce that, seven and a half months later, there ought to have been a further update on the progress of the preparatory work, and the likely trial launch dates by now? As was the case during Winter 2022-2023, when we were anticipating something similar, a trial announcement is looking less likely with each passing day.

Is it possible that there may be a plan B afoot, as some investors here have suggested? My patience with the vague statements, obfuscation, and sheer arrogance from the CEO and his BOD over more than two years has long ran out. I am seriously doubting their competence in taking our treatment forward. Those who maintain that there is still six weeks left in H1 2024 have a point. However, should it always be the case of a last minute update from Synairgen, with a long period of silence beforehand? Good companies are not usually led in such a shabby way, with total disregard for LTIs in particular!